Extra heart recruits for Mesoblast
Friday, 27 February, 2009
A good safety report has allowed recruitment to proceed of a further group of patients for a Phase II trial of Angioblast’s Revascor universal adult stem cell product.
Angioblast, the US-based sister company of Melbourne’s Mesoblast, is conducting a Phase II trial of Revascor in patients with congestive heart failure.
No adverse effects were recorded in the first 20 patients on a low dose of the product. Recruitment will now begin for another 20-person group to receive a higher dose.
The allogeneic stem cell product is being developed to reverse congestive heart failure by rebuilding blood vessels and heart muscle.
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
Self-destructing vaccine protects against TB in monkeys
A self-destructing vaccine administered intravenously provides additional safety and protection...
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
